|Videos|July 16, 2021

The Potential of CAR T-Cell Therapy in Adult ALL

Author(s)Eunice Wang, MD, Bijal D. Shah, MD

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.

This content originally appeared on our sister site, OncLive.

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

The Potential of CAR T-Cell Therapy in Adult ALL

Related Content

Around the Helix: Cell and Gene Therapy Company Updates – May 27, 2026

Evaluating Miv-Cel for Stiff Person Syndrome

Around the Helix: Cell and Gene Therapy Company Updates – May 20, 2026

Phase 3 HOPE-3 Data Reinforce Skeletal and Cardiac Benefits of Deramiocel in Duchenne Muscular Dystrophy

Assessing Miv-Cel for Myasthenia Gravis

Latest CME

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Kentucky Society of Clinical Oncology

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Imaging Matters: Decoding PSMA PET for Better Decision-Making

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

9th Annual School of Nursing Oncology™

Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies